The new injectable drug, Lebrikizumab, branded as Ebglyss, is approved for treating atopic dermatitis in adults and children aged 12 and older who weigh at least 88 pounds.
The researchers noted an interesting trend in the study: a drop in deaths from antimicrobial resistance by around 50% among children younger than 5 and an increase in the same by more than 80% among adults 70 and older.
Medical Daily will always protect your security and privacy. Please read our detailed Privacy Policy
Please do not reply to this email. Click here to adjust your notification preferences or unsubscribe.
